{"generic":"Human Papillomavirus 9-valent Vaccine, Recombinant","drugs":["Gardasil 9","Human Papillomavirus 9-valent Vaccine, Recombinant"],"mono":{"0":{"id":"931316-s-0","title":"Generic Names","mono":"Human Papillomavirus 9-valent Vaccine, Recombinant"},"1":{"id":"931316-s-1","title":"Dosing and Indications","sub":{"0":{"id":"931316-s-1-4","title":"Adult Dosing","mono":"<ul><li>3-dose series, 0.5 mL IM at 0, 2, and 6 months<\/li><li><b>Adenocarcinoma in situ of cervix, Virus types 6, 11, 16, 18, 31, 33, 45, 52, and 58; Prophylaxis:<\/b> (Women, up to 26 years) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Anal cancer, Virus types 16, 18, 31, 33, 45, 52, and 58; Prophylaxis:<\/b> (Women, up to 26 years) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Anal intraepithelial neoplasia, Grades 1, 2, and 3; Prophylaxis:<\/b> (Women, up to 26 years) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Cervical cancer, Virus types 16, 18, 31, 33, 45, 52, and 58; Prophylaxis:<\/b> (Women, up to 26 years) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Cervical intraepithelial neoplasia, Grade 1, 2, 3; Prophylaxis:<\/b> (Women, up to 26 years) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Genital warts, Virus types 6 and 11; Prophylaxis:<\/b> (Women, up to 26 years) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Malignant tumor of vagina, Virus types 16, 18, 31, 33, 45, 52, and 58; Prophylaxis:<\/b> (Women, up to 26 years) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Malignant tumor of vulva, Virus types 16, 18, 31, 33, 45, 52, and 58; Prophylaxis:<\/b> (Women, up to 26 years) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Vaginal intraepithelial neoplasia, Grade 2 and 3; Prophylaxis:<\/b> (Women, up to 26 years) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Vulval intraepithelial neoplasia (VIN), Grade 2 and 3; Prophylaxis:<\/b> (Women, up to 26 years) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><\/ul>"},"1":{"id":"931316-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>3-dose series, 0.5 mL IM at 0, 2, and 6 months; minimum age for vaccination is 9 years and maximum age for vaccination in boys is 15 years<\/li><li><b>Adenocarcinoma in situ of cervix, Virus types 6, 11, 16, 18, 31, 33, 45, 52, and 58; Prophylaxis:<\/b> (Girls, 9 years or older) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Anal cancer, Virus types 16, 18, 31, 33, 45, 52, and 58; Prophylaxis:<\/b> (Girls, 9 years or older) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Anal cancer, Virus types 16, 18, 31, 33, 45, 52, and 58; Prophylaxis:<\/b> (Boys, 9 to 15 years) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Anal intraepithelial neoplasia, Grades 1, 2, and 3; Prophylaxis:<\/b> (Girls, 9 years or older) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Anal intraepithelial neoplasia, Grades 1, 2, and 3; Prophylaxis:<\/b> (Boys, 9 to 15 years) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Cervical cancer, Virus types 16, 18, 31, 33, 45, 52, and 58; Prophylaxis:<\/b> (Girls, 9 years or older) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Cervical intraepithelial neoplasia, Grade 1, 2, 3; Prophylaxis:<\/b> (Girls, 9 years or older) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Genital warts, Virus types 6 and 11; Prophylaxis:<\/b> (Girls, 9 years or older) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Genital warts, Virus types 6 and 11; Prophylaxis:<\/b> (Boys, 9 to 15 years) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Malignant tumor of vagina, Virus types 16, 18, 31, 33, 45, 52, and 58; Prophylaxis:<\/b> (Girls, 9 years or older) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Malignant tumor of vulva, Virus types 16, 18, 31, 33, 45, 52, and 58; Prophylaxis:<\/b> (Girls, 9 years or older) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Vaginal intraepithelial neoplasia, Grade 2 and 3; Prophylaxis:<\/b> (Girls, 9 years or older) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><li><b>Vulval intraepithelial neoplasia (VIN), Grade 2 and 3; Prophylaxis:<\/b> (Girls, 9 years or older) 0.5 mL IM for 3 doses at 0, 2, and 6 months<\/li><\/ul>"},"3":{"id":"931316-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Adenocarcinoma in situ of cervix, Virus types 6, 11, 16, 18, 31, 33, 45, 52, and 58; Prophylaxis<\/li><li>Anal cancer, Virus types 16, 18, 31, 33, 45, 52, and 58; Prophylaxis<\/li><li>Anal intraepithelial neoplasia, Grades 1, 2, and 3; Prophylaxis<\/li><li>Cervical cancer, Virus types 16, 18, 31, 33, 45, 52, and 58; Prophylaxis<\/li><li>Cervical intraepithelial neoplasia, Grade 1, 2, 3; Prophylaxis<\/li><li>Genital warts, Virus types 6 and 11; Prophylaxis<\/li><li>Malignant tumor of vagina, Virus types 16, 18, 31, 33, 45, 52, and 58; Prophylaxis<\/li><li>Malignant tumor of vulva, Virus types 16, 18, 31, 33, 45, 52, and 58; Prophylaxis<\/li><li>Vaginal intraepithelial neoplasia, Grade 2 and 3; Prophylaxis<\/li><li>Vulval intraepithelial neoplasia (VIN), Grade 2 and 3; Prophylaxis<\/li><\/ul>"}}},"3":{"id":"931316-s-3","title":"Contraindications\/Warnings","sub":[{"id":"931316-s-3-9","title":"Contraindications","mono":"<ul><li>Hypersensitivity reactions following a dose of Gardasil(R) or Gardasil(R) 9<\/li><li>Severe allergic reactions to yeast<\/li><\/ul>"},{"id":"931316-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- Syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported; tonic-clonic activity is usually transient and responsive to restoring cerebral perfusion (eg, maintaining a supine or Trendelenburg position); observation for 15 minutes following administration is recommended<\/li><li>Immunologic:<\/li><li>-- Immune response may be decreased in patients who are immunocompromised<\/li><\/ul>"},{"id":"931316-s-3-11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"931316-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"931316-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (Boys, 24.9%; girls and women, 34% to 42.3%), Injection site pain (Boys, 71.5%; girls and women, 89.3% to 90.3%), Swelling at injection site (Boys, 26.9%; girls and women, 40% to 49%)<\/li><li><b>Neurologic:<\/b>Headache (Boys, 9.4%; women and girls, 19.6%)<\/li><\/ul><b>Serious<\/b><br\/><b>Neurologic:<\/b>Syncope<br\/>"},"6":{"id":"931316-s-6","title":"Drug Name Info","sub":{"0":{"id":"931316-s-6-17","title":"US Trade Names","mono":"Gardasil 9<br\/>"},"2":{"id":"931316-s-6-19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"931316-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"931316-s-7","title":"Mechanism Of Action","mono":"Human papillomavirus (HPV) vaccine is thought to protect against anogenital diseases caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 by inducing a humoral immune response.<br\/>"},"9":{"id":"931316-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>For IM administration only<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>Administer in the deltoid region of the upper arm or in the higher anterolateral area of the thigh<\/li><li>Shake well immediately before use; do not dilute or mix with other vaccines<\/li><li>Following administration, observe patient for 15 minutes<\/li><\/ul><\/li><\/ul>"},"10":{"id":"931316-s-10","title":"Monitoring","mono":"signs of syncope, including tonic-clonic movements and other seizure-like activity; for 15 minutes after administration <br\/>"},"13":{"id":"931316-s-13","title":"Clinical Teaching","mono":"<ul><li>Side effects may include pain, swelling, or erythema at the injection site, and headaches.<\/li><li>Instruct patient to complete vaccination series unless contraindicated.<\/li><\/ul>"}}}